---
title: "Danaher Corporation (DHR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DHR.US.md"
symbol: "DHR.US"
name: "Danaher Corporation"
industry: "Life Sciences Tools and Services"
datetime: "2026-05-19T19:14:11.005Z"
locales:
  - [en](https://longbridge.com/en/quote/DHR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DHR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DHR.US.md)
---

# Danaher Corporation (DHR.US)

## Company Overview

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.danaher.com](https://www.danaher.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: C (0.44)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 12 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.02% |  |
| Net Profit YoY | -2.02% |  |
| P/B Ratio | 2.19 |  |
| Dividend Ratio | 0.83% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 115975294940.22 |  |
| Revenue | 24778000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.08% | C |
| Profit Margin | 14.89% | A |
| Gross Margin | 60.34% | A |
| Revenue YoY | 4.02% | C |
| Net Profit YoY | -2.02% | C |
| Total Assets YoY | 5.60% | C |
| Net Assets YoY | 4.13% | C |
| Cash Flow Margin | 174.55% | B |
| OCF YoY | 4.02% | C |
| Turnover | 0.30 | D |
| Gearing Ratio | 36.61% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Danaher Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.02%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-2.02%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.19",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.83%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "115975294940.22",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "24778000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.08%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "14.89%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "60.34%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "4.02%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-2.02%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.60%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.13%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "174.55%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "4.02%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "36.61%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 31.44 | 13/59 | 44.89 | 41.43 | 37.32 |
| PB | 2.19 | 24/59 | 3.08 | 2.81 | 2.61 |
| PS (TTM) | 4.68 | 38/59 | 6.47 | 6.05 | 5.62 |
| Dividend Yield | 0.83% | 3/59 | 0.66% | 0.59% | 0.56% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **25**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 19 | 76% |
| Overweight | 4 | 16% |
| Hold | 2 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 167.35 |
| Highest Target | 310.00 |
| Lowest Target | 205.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DHR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DHR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/DHR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/DHR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**